Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Biopharmaceutical Industry
4.2.2 Rising Demand for Monoclonal Antibodies and Cancer Therapeutics
4.2.3 Growing Production of Biosimilars Due to the Patent Expiry of Branded Therapeutics
4.3 Market Restraints
4.3.1 Strict Regulations
4.3.2 Time Taking Process
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Reagent and Media
5.1.2 Equipment
5.1.3 Others
5.2 By Source
5.2.1 Mammalian Cell Line
5.2.2 Non-Mammalian Cell Line
5.3 By Type of Cell Line
5.3.1 Recombinant Cell Lines
5.3.2 Hybridomas
5.3.3 Continuous Cell Lines
5.3.4 Primary cell lines
5.4 By End-User
5.4.1 Biotech Companies
5.4.2 Academics and Research Institutes
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 American Type Culture Collection (ATCC)
6.1.2 Sartorius AG
6.1.3 Danaher Corporation
6.1.4 Merck KGaA
6.1.5 Thermo Fisher Scientific
6.1.6 WuXi Biologics
6.1.7 Corning Incorporated
6.1.8 Selexis SA
6.1.9 Promega Corporation
6.1.10 GE Healthcare


7 MARKET OPPORTUNITIES AND FUTURE TRENDS